Drugs / SHR-1703
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07701239 | Jul 2026 → Apr 2027 expected | asthma | Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05042401 | Oct 2021 → Jun 2023 | asthma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04855591 | Jun → Sep 2021 | asthma | Atridia Pty Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT04480762 | Aug 2020 → Sep 2021 | asthma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06441812 | Jul 2024 → Sep 2028 expected | T2-high asthma | Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT05522439 | Dec 2022 → Sep 2024 | asthma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05979051 | Nov 2023 → Dec 2028 expected | eosinophilic granulomatosis with polyangiitis | Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06653322 | Nov 2024 → Sep 2027 expected | asthma | Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-1703 | “A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma” NCT06653322 ↗ |
| Action | Inhibit | “an innovative long-acting anti-interleukin-5 monoclonal antibody” PMID 38805242 ↗ Jun 2024 |
| Modality | Monoclonal antibody | “SHR-1703 is a novel humanized IgG1 monoclonal antibody” PMID 38805242 ↗ Jun 2024 |
| Route | Subcutaneous | “administered subcutaneously” NCT04480762 ↗ |
| Target | IL5 | “SHR-1703 is a novel humanized IgG1 monoclonal antibody with high IL-5 affinity” PMID 38805242 ↗ Jun 2024 |